German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics

Planta Medica

Volumn 81, Issue 18, 2015, Pages 1647-1653

  Kuchta, Kenny ^a   Schmidt, Mathias ^b   Nahrstedt, Adolf ^c  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b HerbResearch Germany ^*  (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

drug quality; efficacy; hepatotoxicity; Kava; Piper methysticum; Piperaceae; risk benefit relation

Indexed keywords

KAVA;

ADVERSE DRUG REACTION; DRUG LEGISLATION; DRUG QUALITY; DRUG SAFETY; HUMAN; LIVER TOXICITY; NONHUMAN; PHYTOCHEMISTRY; PIPER METHYSTICUM; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; CHEMISTRY; DRUG EFFECTS; LIVER; MEDICINAL PLANT; POLITICS;

HUMANS; KAVA; LEGISLATION, DRUG; LIVER; PLANTS, MEDICINAL; POLITICS;

EID: 84951311181     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0035-1558295     Document Type: Review

References (55)

1. Anonymous Kava-Kava: Eine Lücke, die keiner wollte. Interview mit Prof. Volker Faust. Natura Med: 2002; 17 14
2. Ernst E. Marktrücknahme des pflanzlichen Anxiolytikums Kava: Nutzen unter-, Risiken überschätzt? Münchn Med Wschr: 2003; 144 40
3. Loew D., Gaus W. Kava-Kava. Tragödie einer Fehlentscheidung. Z Phytother: 2002; 23 267 281
4. Loew D. Zum Widerruf von Kava-Extrakten. Politikum oder fachliche Fehlbeurteilung? Ärzteztsch Naturheilverf: 2003; 44 884 896
5. Loew D. Widerruf der Zulassung von Kava-Extrakten. War die Entscheidung des BfArM gerechtfertigt? Dt Apotheker Ztg: 2005; 145 5362 5364
6. Pittler M. H., Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev: 2003; 1 CD003383
7. Schmidt M., Nahrstedt A. Ist Kava lebertoxisch? Eine Analyse der bekannten Daten zum Leberrisiko von Kava-Präparaten. Dtsch Apoth Ztg: 2002; 142 1006 1011
8. Schmidt M. Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory. J Altern Complement Med: 2003; 9 183 187 author reply 187-188
9. Stevinson C., Huntley A., Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf: 2002; 25 251 261
10. Teschke R., Gaus W., Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine: 2003; 10 440 446
11. Teschke R. Kava-induzierte Leberschäden - Was ist gesichert? Dtsch Apoth Ztg: 2003; 143 4011 4021
12. Teschke R. Nicht einmal eine Verschreibungspflicht. FAZ: 2003; 54 8
13. Singh Y. N., Devkota A. K. Aqueous kava extracts do not affect liver function tests in rats. Planta Med: 2003; 69 496 499
14. Bauer R., Kopp B., Nahrstedt A. Relevant hepatotoxic effects of kava still need to be proven. A statement of the Society for Medicinal Plant Research. Planta Med: 2003; 69 971 972
15. Schmidt M. German court ruling reverses kava ban; German regulatory authority appeals decision. HerbalGram: 2014; 103 38 43
16. Kraft K. Verwaltungsgericht Köln kippt das Kava-Verbot. Z Phytother: 2014; 35 186 189
17. Sarris J., Kavanagh D. J., Byrne G., Bone K. M., Adams J., Deed G. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl): 2009; 205 399 407
18. Sarris J., Kavanagh D. J., Deed G., Bone K. M. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. Hum Psychopharmacol: 2009; 24 41 48
19. Sarris J., Stough C., Bousman C. A., Wahid Z. T., Murray G., Teschke R., Savage K. M., Dowell A., Ng C., Schweitzer I. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol: 2013; 33 643 648
20. Sarris J., Stough C., Teschke R., Wahid Z. T., Bousman C. A., Murray G., Savage K. M., Mouatt P., Ng C., Schweitzer I. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. Phytother Res: 2013; 27 1723 1728
21. Sarris J., Scholey A., Schweitzer I., Bousman C., Laporte E., Ng C., Murray G., Stough C. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. Hum Psychopharmacol: 2012; 27 262 269
22. Schmidt M., Nahrstedt A., Lüpke N. P. Piper methysticum (Kava) in der Diskussion: Betrachtungen zu Qualität, Wirksamkeit und Unbedenklichkeit. Wien Med Wochenschr: 2002; 152 382 388
23. Teschke R., Schwarzenboeck A., Hennermann K. H. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol: 2008; 66 758 766
24. Teschke R., Schwarzenboeck A., Hennermann K. H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol: 2008; 20 1182 1193
25. Teschke R., Frenzel C., Schulze J., Eickhoff A. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol: 2013; 19 2864 2882
26. Teschke R., Fuchs J., Bahre R., Genthner A., Wolff A. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. J Clin Pharm Ther: 2010; 35 545 563
27. Teschke R., Wolff A. Kava hepatotoxicity: regulatory data selection and causality assessment. Dig Liver Dis: 2009; 41 891 901
28. Teschke R., Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate? Regul Toxicol Pharmacol: 2011; 59 1 7
29. Strahl S., Ehret V., Dahm H. H., Maier K. P. Nekrotisierende Hepatitis nach Einnahme pflanzlicher Heilmittel. Dtsch Med Wochenschr: 1998; 123 1410 1414
30. Russmann S., Lauterburg B. H., Helbling A. Kava hepatotoxicity. Ann Intern Med: 2001; 135 68 69
31. Johnson B. M., Qiu S. X., Zhang S., Zhang F., Burdette J. E., Yu L., Bolton J. L., van Breemen R. B. Identification of novel electrophilic metabolites of Piper methysticum Forst (Kava). Chem Res Toxicol: 2003; 16 733 740
32. Olsen L. R., Grillo M. P., Skonberg C. Constituents in kava extracts potentially involved in hepatotoxicity: a review. Chem Res Toxicol: 2011; 24 992 1002
33. Hänsel R., Lazar J. Kawapyrone. Inhaltsstoffe des Rauschpfeffers in pflanzlichen Sedativa. Dtsch Apoth Ztg: 1985; 125 2056 2058
34. Gaedcke F. SL-49: Pharmaceutical characterization of Kava-Kava extracts and their formulations. Phytomed: 2000; 7 02 27
35. Anonymous Assessment of the risk of hepatotoxicity with kava products. Geneva World Health Organization: 2007
36. Lewin L. Über Piper methysticum (Kawa-Kawa). Berl Klin Wschr: 1886; 1 7 10
37. Zhou P., Gross S., Liu J. H., Yu B. Y., Feng L. L., Nolta J., Sharma V., Piwnica-Worms D., Qiu S. X. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. FASEB J: 2010; 24 4722 4732
38. Li X., Liu Z., Xu X., Blair C. A., Sun Z., Xie J., Lilly M. B., Zi X. Kava components down-regulate expression of ar and ar splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One: 2012; 7 e31213
39. Dragull K., Yoshida W. Y., Tang C. S. Piperidine alkaloids from Piper methysticum. Phytochemistry: 2003; 63 193 198
40. Nerurkar P. V., Dragull K., Tang C. S. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol Sci: 2004; 79 106 111
41. Lechtenberg M., Quandt B., Schmidt M., Nahrstedt A. Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Pharmazie: 2008; 63 71 74
42. Teschke R., Qiu S. X., Xuan T. D., Lebot V. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence. Phytother Res: 2011; 25 1263 1274
43. Teschke R., Lebot V. Proposal for a kava quality standardization code. Food Chem Toxicol: 2011; 49 2503 2516
44. Schmidt M., Carreno I., Vergano P. Technical assistance to the integration to the multilateral trading system and support to the integrated framework. Ref: 9 ACP RPR 140-039/11: Establishment of health and safety standards for the production and export of kava-based products. Brussels ACP-EU-TBT: 2012
45. Lebot V. The quality of kava consumed in the South Pacific. HerbalGram: 2006; 71 34 37
46. Schmidt M. Quality criteria for kava. HerbalGram: 2007; 73 44 49
47. Lebot V., Merlin M., Lindstrom L. Kava, the Pacific elixir. New Haven Yale University Press: 1992
48. Siméoni P., Lebot V. Buveurs de kava. Port Vila, Vanuatu Géo-consulte: 2014
49. Lebot V. Kava in the Pacific. High Level Conference on Kava Port Vila, Vanuatu: 2012
50. Kaul P. N., Joshi S. Alternative medicine: herbal drugs and their critical appraisal, Part II. Chapter 2: Kava-Kava. In: Jucker E. editor Progress in drug research, Vol. 57. Basel Springer: 2001; 5 24
51. Narayanapillai S. C., Leitzman P., O'Sullivan M. G., Xing C. Flavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice. Chem Res Toxicol: 2014; 27 1871 1876
52. Lebot V., Do T. K., Legendre L. Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC). Food Chem: 2014; 151 554 560
53. Schmidt M. Noble vs. Two-day Phytochemical quality and analytical specifications. High Level Conference on Kava Port Vila, Vanuatu: 2012
54. Teschke R., Sarris J., Schweitzer I. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol: 2012; 73 170 174
55. Kraft M., Spahn T. W., Menzel J., Senninger N., Dietl K. H., Herbst H., Domschke W., Lerch M. M. Fulminant liver failure after administration of the herbal antidepressant kava-kava. Dtsch Med Wochenschr: 2001; 126 970 972